Keywords
Acute myeloid leukemia
Expression
Clinical significance
Submitted : 2022-08-21
Accepted : 2022-09-05
Published : 2022-09-20
Abstract
Objective: To analyze the expression and clinical significance of miRNA-495 in the peripheral blood of patients with acute myeloid leukemia. Methods: Fifty-six patients with acute myeloid leukemia and 56 healthy controls were selected. Fasting venous blood was drawn and centrifuged, and the plasma was collected. The target miRNA was directly amplified and reverse transcribed into cDNA. The expression of plasma miR-495 was detected by qRT-PCR. Results: The expression level of miRNA-495 in newly diagnosed acute myeloid leukemia (AML [ND]) and relapsed/refractory acute myeloid leukemia (AML [RR]) was significantly lower than that in complete remission (AML [CR]) and normal control group (Control) (p < 0.0001). There was no significant difference between AML (ND) group and AML (RR) group (p > 0.05). The area under the ROC curve (AUC) of miRNA-495 was 0.9503, the 95% confidence interval was 0.9113–0.9892 (p < 0.0001), the standard error was 0.020, the sensitivity and specificity were 91.1% and 92.9%, respectively, and the Jordan index was 0.857. There was no significant difference between the expression level of miRNA-495 and gender, age, leukocyte count, hemoglobin, and platelet count (p > 0.05). However, it was found related to the proportion of primitive bone marrow cells in patients (p = 0.017). Conclusion: The decreased expression of plasma miR-495 in AML patients can be used as a new indicator for the diagnosis and prognosis of AML.
References
Kantarjian HM, Keating MJ, Freireich EJ, 2018, Toward the Potential Cure of Leukemias in the Next Decade. Cancer, 124(22): 4301–4313.
Whiteley AE, Price TT, Cantelli G, et al., 2021, Leukaemia: A Model Metastatic Disease. Nat Rev Cancer, 21(7): 461–475.
Hill M, Tran N, 2021, miRNA Interplay: Mechanisms and Consequences in Cancer. Dis Model Mech, 14(4): dmm047662.
He B, Zhao Z, Cai Q, et al., 2020, miRNA-Based Biomarkers, Therapies, and Resistance in Cancer. Int J Biol Sci, 16(14): 2628–2647.
Liao Q, Wang B, Li X, et al., 2017, miRNAs in Acute Myeloid Leukemia. Oncotarget, 8(2): 3666–3682.
Chen H, Wang X, Bai J, et al., 2017, Expression, Regulation and Function of miR-495 in Healthy and Tumor Tissues. Oncol Lett, 13(4): 2021–2026.
Sharifi H, Jafari Najaf Abadi MH, Razi E, et al., 2019, MicroRNAs and Response to Therapy in Leukemia. J Cell Biochem, 120(9): 14233–14246.
Mardani R, Jafari Najaf Abadi MH, Motieian M, et al., 2019, MicroRNA in Leukemia: Tumor Suppressors and Oncogenes with Prognostic Potential. J Cell Physiol, 234(6): 8465–8486.
Fernandes Q, 2017, MicroRNA: Defining a New Niche in Leukemia. Blood Rev, 31(3): 129–138.
Anelli L, Zagaria A, Specchia G, et al., 2021, Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers. Int J Mol Sci, 22(13): 7156.
Jiang X, Huang H, Li Z, et al., 2012, MiR-495 is a Tumorsuppressor MicroRNA Down-Regulated in MLL-Rearranged Leukemia. Proc Natl Acad Sci U S A, 109(47): 19397–19402.
Li Z, Zhang G, Li D, et al., 2015, Methylation-Associated Silencing of miR-495 Inhibit the Migration and Invasion of Human Gastric Cancer Cells by Directly Targeting PRL-3. Biochem Biophys Res Commun, 456(1): 344–350.
Chu H, Chen X, Wang H, et al., 2014, MiR-495 Regulates Proliferation and Migration in NSCLC by Targeting MTA3. Tumour Biol, 35(4): 3487–3494.
Chen SM, Chen HC, Chen SJ, et al., 2013, MicroRNA-495 Inhibits Proliferation of Glioblastoma Multiforme Cells by Down Regulating Cyclin-Dependent Kinase 6. World J Surg Oncol, 11(1): 87.
Du C, Lv C, Feng Y, et al., 2020, Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B Axis Facilitates Prostate Cancer Progression. J Exp Clin Cancer Res, 39(1): 223.
Liu C, Sun B, An N, et al., 2011, Inhibitory Effect of Survivin Promoter-Regulated Oncolytic Adenovirus Carrying P53 Gene Against Gallbladder Cancer. Mol Oncol, 5(6): 545–554.
Alkhathami AG, Verma AK, Alfaifi M, et al., 2021, Role of miRNA-495 and NRXN-1 and CNTN-1 mRNA Expression and Its Prognostic Importance in Breast Cancer Patients. J Oncol, 2021: 9657071.
Zhang R, Guo C, Liu T, et al., 2021, MicroRNA miR-495 Regulates the Development of Hepatocellular Carcinoma by Targeting C1q/Tumor Necrosis Factor-Related Protein-3 (CTRP3). Bioengineered, 12(1): 6902–6912.
Cao M, Nie W, Li J, et al., 2014, MicroRNA-495 Induces Breast Cancer Cell Migration by Targeting JAM-A. Protein & Cell, 5(11): 862–872.
Wang YY, Zhang ZR, Li J, et al., 2021, Expression of miR-495 and Its Effect on MHCC-97H Hepatocellular Carcinoma Cells. Zhonghua Gan Zang Bing Za Zhi, 29(6): 571–574.